Olaparib vs Talazoparib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: PARP · full HR+/HER2- Metastatic Breast Cancer pipeline
Olaparib
Marketed by AstraZeneca and partners
NCT02000622 · Phase 3 · completed
The trial randomly assigned 302 participants to olaparib or active chemotherapy, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, independently reviewed progression-free survival, was met: median PFS was 7.0 versus 4.2 months, with a hazard ratio of 0.58 (95% CI 0.43–0.80; p=0.0009).
Next expected readout: January 2027 · NCT04683679 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3) (met)
Result source: NCT02000622
Talazoparib
Marketed by Pfizer and partners
NCT01945775 · Phase 3 · completed
Participants were randomized 2:1 to talazoparib or physician’s-choice chemotherapy, with 287 and 144 participants respectively, but treatment assignment was not blinded. The primary radiologic progression-free survival endpoint was met, with a statistically significant benefit for talazoparib; the open-label design and nonsignificant overall-survival result support a moderate evidence grade.
Next expected readout: January 2027 · NCT04039230 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7) (met)
Result source: NCT01945775
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olaparib | Talazoparib |
|---|---|---|
| PFS, median | 7 vs 4.2vs ChemotherapyNCT020006223 other results
| 8.6 vs 5.6vs Physician's Choice TreatmentNCT019457758 other results
|
| OS, median | 19.3 vs 19.6vs ChemotherapyNCT020006224 other results
| 19.3 vs 19.5vs Physician's Choice TreatmentNCT01945775 |
| ORR | 49.6%bNCT03286842 | 62.6% vs 27.2%vs Physician's Choice TreatmentNCT01945775 |
| Clinical benefit rate | —Trial running · NCT02810743 | —Not reported |
PFS, median
- Olaparib
- 7 vs 4.2vs ChemotherapyNCT02000622
3 other results
- 8.2 NCT03286842
- 7.4 vs 4.2 NCT02000622
- 1.8 NCT03205761
- Talazoparib
- 8.6 vs 5.6vs Physician's Choice TreatmentNCT01945775
8 other results
- 6.8 NCT01286987
- 7.4 NCT01286987
- 1.2 NCT01286987
- 1.4 NCT01286987
- 2.6 NCT01286987
- 2.8 NCT01286987
- 3.4 NCT03343054
- 3 NCT03343054
OS, median
- Olaparib
- 19.3 vs 19.6vs ChemotherapyNCT02000622
4 other results
- 19.3 vs 17.1 NCT02000622
- 19.3 vs 17.1 NCT02000622
- 24.9 NCT03286842
- 8.9 NCT03205761
- Talazoparib
- 19.3 vs 19.5vs Physician's Choice TreatmentNCT01945775
ORR
- Olaparib
- 49.6%bNCT03286842
- Talazoparib
- 62.6% vs 27.2%vs Physician's Choice TreatmentNCT01945775
Clinical benefit rate
- Olaparib
- —Trial running · NCT02810743
- Talazoparib
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Olaparib: 7 of 7 rows · Talazoparib: 6 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olaparib Rows use multiple source trials | Talazoparib Rows use multiple source trials |
|---|---|---|
| Duration of Response time to event · months No placebo or comparator arm | 8 monthsa,b,c,d NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 1 other source trial18.4 months NCT03205761 · Phase 2 · registry result, not featured evidence | 7.43 months*e,a,b,c,d NCT01286987 · Phase 1 · registry result, not featured evidence · converted to months from 32.2 weeks as posted show 3 more doses6.21 months* NCT01286987 · Phase 1 · registry result, not featured evidence · converted to months from 26.9 weeks as posted NA months NCT01286987 · Phase 1 · registry result, not featured evidence 3.14 months* NCT01286987 · Phase 1 · registry result, not featured evidence · converted to months from 13.6 weeks as posted |
| ORR event count · % of participants No placebo or comparator arm | 9.1% (n=11) @ 8wk*f,b,c,d NCT03205761 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted | 40% (n=20)*e,f,b,c,d NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 8 participants as posted show 6 more doses0% (n=14)* NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted 38.7% (n=31)* NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 12 participants as posted 15.4% (n=13)* NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 2 participants as posted 0% (n=1)* NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted 0% (n=2)* NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 0 participants as posted 8.7% (n=23)* NCT01286987 · Phase 1 · registry result, not featured evidence · converted to % from 2 participants as posted |
| PFS time to event · months No placebo or comparator arm | 8.18 monthsa,b,c,d NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 1 other source trial1.8 months @ 8wk NCT03205761 · Phase 2 · registry result, not featured evidence | 3.4 months1.0 mge,a,b,c,d NCT03343054 · Phase 1 · registry result, not featured evidence show 1 more dose3 months0.75 mg NCT03343054 · Phase 1 · registry result, not featured evidence |
| Dropout rate | 82.4%300 mg bdg NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 6 more results—Olaparib gBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Olaparib sBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 0%Both Ovarian Cancer and Breast Can NCT04330040 · Phase 4 · registry result, not featured evidence 52.6%Breast Cancer NCT04330040 · Phase 4 · registry result, not featured evidence 36.2%Ovarian Cancer NCT04330040 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT03205761 · Phase 2 · registry result, not featured evidence | n/a: no completion milestoneh NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 25 more results0%Cohort A - Triple-negative Breast NCT02401347 · Phase 2 · registry result, not featured evidence 0%Cohort B - HER2-negative Solid Tum NCT02401347 · Phase 2 · registry result, not featured evidence 5%Expansion Arm Talazoparib (6 Month NCT02282345 · Phase 2 · registry result, not featured evidence · combination 0%Talazoparib (2 Months) NCT02282345 · Phase 2 · registry result, not featured evidence n/a: no completion milestone1.0 mg NCT03343054 · Phase 1 · registry result, not featured evidence —1.0 mg NCT03343054 · Phase 1 · registry result, not featured evidence n/a: no completion milestone0.75 mg NCT03343054 · Phase 1 · registry result, not featured evidence —Treatment A: Commercial Capsule Fa NCT04672460 · Phase 1 · registry result, not featured evidence —Treatment B: Soft Gel Capsule Fast NCT04672460 · Phase 1 · registry result, not featured evidence —Treatment C: Soft Gel Capsule Fed NCT04672460 · Phase 1 · registry result, not featured evidence 83.3%1000 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 100%1100 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 83.3%900 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 100%600 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 100%400 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 100%200 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 100%100 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 100%50 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 100%25 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Breast Cancer NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Ewing Cancer) NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Ovarian/ Peri NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Pancreatic Ca NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Prostate Canc NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (SCLC Cancer) NCT01286987 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —300 mg bdg NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 6 more results—Olaparib gBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Olaparib sBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 0%Both Ovarian Cancer and Breast Can NCT04330040 · Phase 4 · registry result, not featured evidence 0%Breast Cancer NCT04330040 · Phase 4 · registry result, not featured evidence 3.1%Ovarian Cancer NCT04330040 · Phase 4 · registry result, not featured evidence — NCT03205761 · Phase 2 · registry result, not featured evidence | —h NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 25 more results—Cohort A - Triple-negative Breast NCT02401347 · Phase 2 · registry result, not featured evidence —Cohort B - HER2-negative Solid Tum NCT02401347 · Phase 2 · registry result, not featured evidence —Expansion Arm Talazoparib (6 Month NCT02282345 · Phase 2 · registry result, not featured evidence · combination —Talazoparib (2 Months) NCT02282345 · Phase 2 · registry result, not featured evidence —1.0 mg NCT03343054 · Phase 1 · registry result, not featured evidence —1.0 mg NCT03343054 · Phase 1 · registry result, not featured evidence —0.75 mg NCT03343054 · Phase 1 · registry result, not featured evidence —Treatment A: Commercial Capsule Fa NCT04672460 · Phase 1 · registry result, not featured evidence —Treatment B: Soft Gel Capsule Fast NCT04672460 · Phase 1 · registry result, not featured evidence —Treatment C: Soft Gel Capsule Fed NCT04672460 · Phase 1 · registry result, not featured evidence —1000 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —1100 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —900 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —600 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —400 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —200 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —100 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —50 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —25 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Breast Cancer NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Ewing Cancer) NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Ovarian/ Peri NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Pancreatic Ca NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (Prostate Canc NCT01286987 · Phase 1 · registry result, not featured evidence —Part 2: Talazoparib (SCLC Cancer) NCT01286987 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 18%300 mg bdg NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 6 more results12.7%Olaparib gBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 33.3%Olaparib sBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 100%Both Ovarian Cancer and Breast Can NCT04330040 · Phase 4 · registry result, not featured evidence 18.4%Breast Cancer NCT04330040 · Phase 4 · registry result, not featured evidence 14.9%Ovarian Cancer NCT04330040 · Phase 4 · registry result, not featured evidence 36.4% NCT03205761 · Phase 2 · registry result, not featured evidence | 36%h NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 25 more results0%Cohort A - Triple-negative Breast NCT02401347 · Phase 2 · registry result, not featured evidence 15%Cohort B - HER2-negative Solid Tum NCT02401347 · Phase 2 · registry result, not featured evidence 5%Expansion Arm Talazoparib (6 Month NCT02282345 · Phase 2 · registry result, not featured evidence · combination 0%Talazoparib (2 Months) NCT02282345 · Phase 2 · registry result, not featured evidence 0%1.0 mg NCT03343054 · Phase 1 · registry result, not featured evidence 5.3%1.0 mg NCT03343054 · Phase 1 · registry result, not featured evidence 33.3%0.75 mg NCT03343054 · Phase 1 · registry result, not featured evidence 13.8%Treatment A: Commercial Capsule Fa NCT04672460 · Phase 1 · registry result, not featured evidence 11.7%Treatment B: Soft Gel Capsule Fast NCT04672460 · Phase 1 · registry result, not featured evidence 3.3%Treatment C: Soft Gel Capsule Fed NCT04672460 · Phase 1 · registry result, not featured evidence 33.3%1000 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 50%1100 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 50%900 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 33.3%600 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 0%400 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 100%200 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 66.7%100 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 66.7%50 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 33.3%25 mcg/day NCT01286987 · Phase 1 · registry result, not featured evidence 16.7%Part 2: Talazoparib (Breast Cancer NCT01286987 · Phase 1 · registry result, not featured evidence 33.3%Part 2: Talazoparib (Ewing Cancer) NCT01286987 · Phase 1 · registry result, not featured evidence 45.5%Part 2: Talazoparib (Ovarian/ Peri NCT01286987 · Phase 1 · registry result, not featured evidence 60%Part 2: Talazoparib (Pancreatic Ca NCT01286987 · Phase 1 · registry result, not featured evidence 0%Part 2: Talazoparib (Prostate Canc NCT01286987 · Phase 1 · registry result, not featured evidence 34.8%Part 2: Talazoparib (SCLC Cancer) NCT01286987 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 300 mg bdg nausea 58% anaemia 37.1% vomiting 32.2% NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 6 more resultsnausea 55.6% anaemia 38.9% asthenia 27.8% NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 constipation 100% asthenia 66.7% diarrhoea 66.7% NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 asthenia 100% abdominal pain 0% anaemia 0% NCT04330040 · Phase 4 · registry result, not featured evidence anaemia 36.8% decreased appetite 13.2% thrombocytopenia 13.2% NCT04330040 · Phase 4 · registry result, not featured evidence anaemia 50.9% thrombocytopenia 21.7% nausea 20.5% NCT04330040 · Phase 4 · registry result, not featured evidence asthenia 27.3% abdominal pain upper 18.2% headache 18.2% NCT03205761 · Phase 2 · registry result, not featured evidence | h anaemia 53.5% fatigue 51.4% nausea 49.7% NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 25 more resultsanemia 100% abdominal pain 0% alanine aminotransferase increased 0% NCT02401347 · Phase 2 · registry result, not featured evidence anemia 75% nausea 75% fatigue 70% NCT02282345 · Phase 2 · registry result, not featured evidence · combination anemia 69.2% decreased white blood cells 61.5% dizziness 61.5% NCT02282345 · Phase 2 · registry result, not featured evidence 1.0 mg anaemia 33.3% platelet count decreased 33.3% rash maculo-papular 33.3% NCT03343054 · Phase 1 · registry result, not featured evidence 1.0 mg anaemia 68.4% neutrophil count decreased 63.2% white blood cell count decreased 42.1% NCT03343054 · Phase 1 · registry result, not featured evidence 0.75 mg alanine aminotransferase increased 33.3% arthralgia 33.3% blood alkaline phosphatase increased 33.3% NCT03343054 · Phase 1 · registry result, not featured evidence anaemia 10.8% nausea 10.8% decreased appetite 7.7% NCT04672460 · Phase 1 · registry result, not featured evidence fatigue 18.3% anaemia 13.3% decreased appetite 8.3% NCT04672460 · Phase 1 · registry result, not featured evidence anaemia 16.7% abdominal pain 6.7% alopecia 6.7% NCT04672460 · Phase 1 · registry result, not featured evidence 1000 mcg/day fatigue 83.3% alopecia 66.7% anaemia 66.7% NCT01286987 · Phase 1 · registry result, not featured evidence 1100 mcg/day cough 50% abdominal pain 33.3% anaemia 33.3% NCT01286987 · Phase 1 · registry result, not featured evidence 900 mcg/day nausea 83.3% alopecia 50% constipation 50% NCT01286987 · Phase 1 · registry result, not featured evidence 600 mcg/day nausea 66.7% wheezing 66.7% cough 50% NCT01286987 · Phase 1 · registry result, not featured evidence 400 mcg/day fatigue 100% constipation 66.7% nausea 66.7% NCT01286987 · Phase 1 · registry result, not featured evidence 200 mcg/day nausea 100% abdominal pain 66.7% constipation 66.7% NCT01286987 · Phase 1 · registry result, not featured evidence 100 mcg/day fatigue 66.7% abdominal distension 33.3% abdominal pain 33.3% NCT01286987 · Phase 1 · registry result, not featured evidence 50 mcg/day flatulence 66.7% abdominal pain 33.3% anastomotic stenosis 33.3% NCT01286987 · Phase 1 · registry result, not featured evidence 25 mcg/day diarrhoea 66.7% anxiety 33.3% bundle branch block left 33.3% NCT01286987 · Phase 1 · registry result, not featured evidence fatigue 50% alopecia 41.7% anaemia 41.7% NCT01286987 · Phase 1 · registry result, not featured evidence anaemia 41.7% arthralgia 33.3% back pain 25% NCT01286987 · Phase 1 · registry result, not featured evidence nausea 90.9% fatigue 81.8% alopecia 54.5% NCT01286987 · Phase 1 · registry result, not featured evidence fatigue 40% nausea 40% abdominal pain 30% NCT01286987 · Phase 1 · registry result, not featured evidence constipation 66.7% anaemia 33.3% arthralgia 33.3% NCT01286987 · Phase 1 · registry result, not featured evidence fatigue 52.2% nausea 39.1% anaemia 34.8% NCT01286987 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 1.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 2 versus Phase 1.
- gPopulation comparability has not been reviewed for 4 of these studies.
- hPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olaparib
show 1 more result
Talazoparib
show 9 more results
show 9 more results
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
Breast Cancer
Shared mechanism: PARP · full Breast Cancer pipeline
Olaparib
Marketed by AstraZeneca and partners
NCT02000622 · Phase 3 · completed
The trial randomly assigned 302 participants to olaparib or active chemotherapy, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, independently reviewed progression-free survival, was met: median PFS was 7.0 versus 4.2 months, with a hazard ratio of 0.58 (95% CI 0.43–0.80; p=0.0009).
Next expected readout: December 2026 · NCT03740893 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3) (met)
Result source: NCT02000622
Talazoparib
Marketed by Pfizer and partners
NCT01945775 · Phase 3 · completed
Participants were randomized 2:1 to talazoparib or physician’s-choice chemotherapy, with 287 and 144 participants respectively, but treatment assignment was not blinded. The primary radiologic progression-free survival endpoint was met, with a statistically significant benefit for talazoparib; the open-label design and nonsignificant overall-survival result support a moderate evidence grade.
Next expected readout: January 2027 · NCT04039230 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7) (met)
Result source: NCT01945775
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Olaparib: 6 of 6 rows · Talazoparib: 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olaparib | Talazoparib |
|---|---|---|
| Overall Survival time to event · months | 19.3 vs 19.6 Chemotherapy months300 mg bda,b,c NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 2 more doses19.3 vs 17.1 Chemotherapy months300 mg bd NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 19.3 vs 17.1 Chemotherapy months300 mg bd NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 19.3 vs 19.5 Physician's Choice Treatment monthsb,c NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| PFS time to event · months | 7 vs 4.2 Chemotherapy months300 mg bda,b,c NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose7.4 vs 4.2 Chemotherapy months300 mg bd NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | 8.6 vs 5.6 Physician's Choice Treatment monthsb,c NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | 82.4%300 mg bdd NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more results—Olaparib gBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Olaparib sBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 0%Both Ovarian Cancer and Breast Can NCT04330040 · Phase 4 · registry result, not featured evidence 52.6%Breast Cancer NCT04330040 · Phase 4 · registry result, not featured evidence 36.2%Ovarian Cancer NCT04330040 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT03205761 · Phase 2 · registry result, not featured evidence 50% NCT03167619 · Phase 2 · registry result, not featured evidence · combination | n/a: no completion milestonee NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more results0%Cohort A - Triple-negative Breast NCT02401347 · Phase 2 · registry result, not featured evidence 0%Cohort B - HER2-negative Solid Tum NCT02401347 · Phase 2 · registry result, not featured evidence 5%Expansion Arm Talazoparib (6 Month NCT02282345 · Phase 2 · registry result, not featured evidence · combination 0%Talazoparib (2 Months) NCT02282345 · Phase 2 · registry result, not featured evidence —Treatment A: Commercial Capsule Fa NCT04672460 · Phase 1 · registry result, not featured evidence —Treatment B: Soft Gel Capsule Fast NCT04672460 · Phase 1 · registry result, not featured evidence —Treatment C: Soft Gel Capsule Fed NCT04672460 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —300 mg bdd NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more results—Olaparib gBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Olaparib sBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 0%Both Ovarian Cancer and Breast Can NCT04330040 · Phase 4 · registry result, not featured evidence 0%Breast Cancer NCT04330040 · Phase 4 · registry result, not featured evidence 3.1%Ovarian Cancer NCT04330040 · Phase 4 · registry result, not featured evidence — NCT03205761 · Phase 2 · registry result, not featured evidence — NCT03167619 · Phase 2 · registry result, not featured evidence · combination | —e NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more results—Cohort A - Triple-negative Breast NCT02401347 · Phase 2 · registry result, not featured evidence —Cohort B - HER2-negative Solid Tum NCT02401347 · Phase 2 · registry result, not featured evidence —Expansion Arm Talazoparib (6 Month NCT02282345 · Phase 2 · registry result, not featured evidence · combination —Talazoparib (2 Months) NCT02282345 · Phase 2 · registry result, not featured evidence —Treatment A: Commercial Capsule Fa NCT04672460 · Phase 1 · registry result, not featured evidence —Treatment B: Soft Gel Capsule Fast NCT04672460 · Phase 1 · registry result, not featured evidence —Treatment C: Soft Gel Capsule Fed NCT04672460 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 18%300 mg bdd NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more results12.7%Olaparib gBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 33.3%Olaparib sBRCAm Cohort NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 100%Both Ovarian Cancer and Breast Can NCT04330040 · Phase 4 · registry result, not featured evidence 18.4%Breast Cancer NCT04330040 · Phase 4 · registry result, not featured evidence 14.9%Ovarian Cancer NCT04330040 · Phase 4 · registry result, not featured evidence 36.4% NCT03205761 · Phase 2 · registry result, not featured evidence 13.6% NCT03167619 · Phase 2 · registry result, not featured evidence · combination | 36%e NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more results0%Cohort A - Triple-negative Breast NCT02401347 · Phase 2 · registry result, not featured evidence 15%Cohort B - HER2-negative Solid Tum NCT02401347 · Phase 2 · registry result, not featured evidence 5%Expansion Arm Talazoparib (6 Month NCT02282345 · Phase 2 · registry result, not featured evidence · combination 0%Talazoparib (2 Months) NCT02282345 · Phase 2 · registry result, not featured evidence 13.8%Treatment A: Commercial Capsule Fa NCT04672460 · Phase 1 · registry result, not featured evidence 11.7%Treatment B: Soft Gel Capsule Fast NCT04672460 · Phase 1 · registry result, not featured evidence 3.3%Treatment C: Soft Gel Capsule Fed NCT04672460 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 300 mg bdd nausea 58% anaemia 37.1% vomiting 32.2% NCT02000622 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more resultsnausea 55.6% anaemia 38.9% asthenia 27.8% NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 constipation 100% asthenia 66.7% diarrhoea 66.7% NCT03286842 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 asthenia 100% abdominal pain 0% anaemia 0% NCT04330040 · Phase 4 · registry result, not featured evidence anaemia 36.8% decreased appetite 13.2% thrombocytopenia 13.2% NCT04330040 · Phase 4 · registry result, not featured evidence anaemia 50.9% thrombocytopenia 21.7% nausea 20.5% NCT04330040 · Phase 4 · registry result, not featured evidence asthenia 27.3% abdominal pain upper 18.2% headache 18.2% NCT03205761 · Phase 2 · registry result, not featured evidence decreased appetite 40.9% nausea 40.9% anaemia 31.8% NCT03167619 · Phase 2 · registry result, not featured evidence · combination | e anaemia 53.5% fatigue 51.4% nausea 49.7% NCT01945775 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more resultsanemia 100% abdominal pain 0% alanine aminotransferase increased 0% NCT02401347 · Phase 2 · registry result, not featured evidence anemia 75% nausea 75% fatigue 70% NCT02282345 · Phase 2 · registry result, not featured evidence · combination anemia 69.2% decreased white blood cells 61.5% dizziness 61.5% NCT02282345 · Phase 2 · registry result, not featured evidence anaemia 10.8% nausea 10.8% decreased appetite 7.7% NCT04672460 · Phase 1 · registry result, not featured evidence fatigue 18.3% anaemia 13.3% decreased appetite 8.3% NCT04672460 · Phase 1 · registry result, not featured evidence anaemia 16.7% abdominal pain 6.7% alopecia 6.7% NCT04672460 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for 5 of these studies.
- ePopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olaparib
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
Talazoparib
show 3 more results
show 3 more results
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olaparib's landscape · Talazoparib's landscape